Lynparza in combination with abiraterone granted priority review in US
New therapy is aimed at patients with metastatic castration-resistant prostate cancer
Read Moreby John Pinching | Aug 16, 2022 | News | 0
New therapy is aimed at patients with metastatic castration-resistant prostate cancer
Read Moreby Lucy Parsons | Aug 3, 2021 | News | 0
Tecentriq is first and only cancer immunotherapy with positive Phase III results in adjuvant lung cancer setting
Read Moreby Lucy Parsons | Jan 6, 2021 | News | 0
AZ is aiming for approval in adults with and without type 2 diabetes
Read Moreby Lucy Parsons | Dec 9, 2020 | News | 0
Vaccine candidate previously scored fast-track and breakthrough therapy designations
Read Moreby Selina McKee | Aug 19, 2020 | News | 0
AZ says approval would “simplify and improve treatment by enabling continuity of care while minimising the risk of exposure to infection in the healthcare setting”
Read Moreby Anna Smith | Jan 7, 2020 | News | 0
The US FDA accepted a supplemental New Drug Application for the treatment.
Read Moreby Anna Smith | Aug 22, 2019 | News | 0
Back in February, the companies revealed results from the Phase III ARCHES trial in men with mHSPC.
Read Moreby Anna Smith | Jul 18, 2019 | News | 0
The governing body accepted the company’s Biologics License Application for prevention of vaso-occlusive crises.
Read Moreby Anna Smith | Jun 25, 2019 | News | 0
There are around 7,500 new ovarian cancer cases in the UK every year.
Read Moreby Anna Smith | Mar 8, 2019 | News | 0
US regulators have accepted Sanofi’s Dupixent for Priority Review as a treatment for rhinosinusitis with nasal polyps.
Read Moreby Anna Smith | Feb 20, 2019 | News | 0
Roche has announced that the FDA has granted Priority Review for entrectinib as a treatment for NTRK fusion-positive, locally advanced or metastatic solid tumours, and to treat metastatic ROS1-positive non-small-cell lung cancer.
Read Moreby Anna Smith | Feb 13, 2019 | News | 0
The US Food and Drug Administration has accepted for priority review a supplemental Biologics License Application for Merck’s Bavencio (avelumab) in combination with Inlyta (axitinib) for patients with advanced renal cell carcinoma (RCC).
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
